Dermatologists, as well as specialists in other therapeutic areas, e.g., gastroenterology, rheumatology, dermatology, surgery, gynecologists, urologists, plastic surgeons, emergency room health care providers, and primary care physicians including pediatricians.

After completing this activity, the participant should be better able to:

• Assess the prevalence of metabolic comorbidities in patients with psoriatic disease and their impact on morbidity and mortality 
• Implement current guidelines for the assessment and management of PsO/PsA and associated metabolic comorbidities, including obesity, diabetes, cardiovascular disease, and dyslipidemia
• Evaluate the role of GLP-1R agonists in the management of MetS in patients with PsO/PsA